10/1/2008 - Michael L. Socol, MD
Editor: Pamela D. Berens, MD
Toxoplasma gondii is a protozoan which can lead to human infection through infected uncooked meat, exposure to contaminated soil or water, eating soil contaminated fruits or vegetables, or exposure to infected cat feces. Most infections are asymptomatic, but immunocompromised hosts (e.g. HIV infected individuals) can manifest such problems as central nervous system infection, myocarditis, or pneumonitis. The diagnosis is made by serology showing seroconversion from negative to positive IgM or IgG antibodies. Conversion requires confirmation in a reference laboratory. Maternal IgG avidity testing may also be useful to assist with timing the primary infection for patient counseling.
Congenital infection is most likely to occur following maternal infection in the third trimester, although first trimester fetal infection is most severe. Most infected fetuses are asymptomatic at birth. Characteristic ultrasound findings include hyperechoic intracranial calcifications and ventriculomegaly, which carry a poor prognosis. The diagnosis of congenital infection can be confirmed by PCR of amniotic fluid. Uncertainty surrounding treatment efficacy persists, although treatment is generally recommended. Treatment may include pyrimethamine, sulfadiazine and folinic acid in addition to using spiramycin to reduce transplacental transfer of the parasite. Efforts in the United States are primarily directed toward prevention of infection rather than routine screening. Careful hand washing, washing of fruits and vegetables, and avoidance of cat litter or uncooked meat are all advised.
Duff P, Creasy RK, Resnik R, et al., Maternal-Fetal Medicine: Principles and Practice. Maternal and fetal infections. 7th Edition, Saunders, 2013.
American College of Obstetricians and Gynecologists. Practice Bulletin No. 151. Cytomegalovirus, parvovirus B19, varicella zoster, and toxoplasmosis in pregnancy. Obstet Gynecol. 2015 Jun;125(6):1510-25. doi: 10.1097/01.AOG.0000466430.19823.53.
Initial approval October 2008; Revised January 2015, July 2016; Reaffirmed January 2018.
********** Notice Regarding Use ************
The Foundation for Exxcellence in Women’s Health, Inc (“Foundation”) is committed to accuracy and will review and validate all Pearls on an ongoing basis to reflect current practice.
This document is designed to aid practitioners in providing appropriate obstetric and gynecologic care. Recommendations are derived from major society guidelines and high quality evidence when available, supplemented by the opinion of the author and editorial board when necessary. It should not be construed as dictating an exclusive course of treatment or procedure to be followed.
Variations in practice may be warranted when, in the reasonable judgment of the treating clinician, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology. The Foundation reviews the articles regularly; however, its publications may not reflect the most recent evidence. While we make every effort to present accurate and reliable information, this publication is provided “as is” without any warranty of accuracy, reliability, or otherwise, either express or implied. The Foundation does not guarantee, warrant, or endorse the products or services of any firm, organization, or person. Neither the Foundation, the ABOG, SASGOG nor their respective officers, directors, members, employees, or agents will be liable for any loss, damage, or claim with respect to any liabilities, including direct, special, indirect, or consequential damages, incurred in connection with this publication or reliance on the information presented.
Copyright 2018 - The Foundation for Exxcellence in Women's Health, Inc. All rights reserved. No publication, reuse or dissemination allowed without written permission.
Visit us at: www.exxcellence.org
Back to Search Results